112 related articles for article (PubMed ID: 12086483)
1. Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Rizzo RC; Udier-Blagović M; Wang DP; Watkins EK; Kroeger Smith MB; Smith RH; Tirado-Rives J; Jorgensen WL
J Med Chem; 2002 Jul; 45(14):2970-87. PubMed ID: 12086483
[TBL] [Abstract][Full Text] [Related]
2. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
Rizzo RC; Tirado-Rives J; Jorgensen WL
J Med Chem; 2001 Jan; 44(2):145-54. PubMed ID: 11170624
[TBL] [Abstract][Full Text] [Related]
3. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.
Smith RH; Jorgensen WL; Tirado-Rives J; Lamb ML; Janssen PA; Michejda CJ; Kroeger Smith MB
J Med Chem; 1998 Dec; 41(26):5272-86. PubMed ID: 9857095
[TBL] [Abstract][Full Text] [Related]
4. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.
Smith MB; Ruby S; Horouzhenko S; Buckingham B; Richardson J; Puleri I; Potts E; Jorgensen WL; Arnold E; Zhang W; Hughes SH; Michejda CJ; Smith RH
Drug Des Discov; 2003; 18(4):151-63. PubMed ID: 15553926
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
8. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
[TBL] [Abstract][Full Text] [Related]
9. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Zhou T; Xie L
Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
[No Abstract] [Full Text] [Related]
10. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors.
Geitmann M; Unge T; Danielson UH
J Med Chem; 2006 Apr; 49(8):2367-74. PubMed ID: 16610780
[TBL] [Abstract][Full Text] [Related]
11. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
Treesuwan W; Hannongbua S
J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
[TBL] [Abstract][Full Text] [Related]
12. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA.
Wang J; Morin P; Wang W; Kollman PA
J Am Chem Soc; 2001 Jun; 123(22):5221-30. PubMed ID: 11457384
[TBL] [Abstract][Full Text] [Related]
13. Analyses of activity for factor Xa inhibitors based on Monte Carlo simulations.
Ostrovsky D; Udier-Blagović M; Jorgensen WL
J Med Chem; 2003 Dec; 46(26):5691-9. PubMed ID: 14667222
[TBL] [Abstract][Full Text] [Related]
14. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Med Chem; 2004 Apr; 47(9):2389-92. PubMed ID: 15084137
[TBL] [Abstract][Full Text] [Related]
15. Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase.
Udier-Blagović M; Watkins EK; Tirado-Rives J; Jorgensen WL
Bioorg Med Chem Lett; 2003 Oct; 13(19):3337-40. PubMed ID: 12951121
[TBL] [Abstract][Full Text] [Related]
16. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
Ribone SR; Quevedo MA; Madrid M; Briñón MC
J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and anti-HIV-1 activity of 1-aromatic methyl-substituted 3-(3,5-dimethylbenzyl)uracil and N-3,5-dimethylbenzyl-substituted urea derivatives.
Sakakibara N; Baba M; Okamoto M; Toyama M; Demizu Y; Misawa T; Kurihara M; Irie K; Kato Y; Maruyama T
Antivir Chem Chemother; 2015 Feb; 24(1):3-18. PubMed ID: 26149262
[TBL] [Abstract][Full Text] [Related]
18. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
Sengupta D; Verma D; Naik PK
In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
[TBL] [Abstract][Full Text] [Related]
19. Monte Carlo sampling and multivariate adaptive regression splines as tools for QSAR modelling of HIV-1 reverse transcriptase inhibitors.
Alamdari RF; Mani-Varnosfaderani A; Asadollahi-Baboli M; Khalafi-Nezhad A
SAR QSAR Environ Res; 2012 Oct; 23(7-8):665-82. PubMed ID: 22746992
[TBL] [Abstract][Full Text] [Related]
20. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
